吉西他滨与持续输注5-氟尿嘧啶作为难治性结直肠癌患者的三线化疗方案

Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients.

作者信息

Bitossi Raffaella, Sculli Carla Maria, Tampellini Marco, Alabiso Irene, Brizzi Maria Pia, Ferrero Anna, Ottone Azzurra, Bellini Elisa, Gorzegno Gabriella, Berruti Alfredo, Dogliotti Luigi

机构信息

Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliero Universitaria San Luigi, 10043 Orbassano, Torino, Italy.

出版信息

Anticancer Res. 2008 Sep-Oct;28(5B):3055-60.

PMID:19031956

Abstract

BACKGROUND

There is no standard treatment for patients with advanced colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment and having good performance status (PS).

PATIENTS AND METHODS

We investigated gemcitabine 1,000 mg/m2 days 1, 8 and 15 q28d combined with protracted 5-fluorouracil continuous infusion at 200 mg/m2/day, in 37 consecutive patients progressing after oxaliplatin-irinotecan-containing chemotherapies.

RESULTS

Partial response (PR) was achieved in 4 (10.8%) and disease stabilization (SD) in 19 (51.4%) cases (PR+SD: 62.2%). Median time to progression and survival were 4.2 and 8.9 months, respectively. Grade III toxicities were thrombocytopenia, neutropenia (in 3 patients) and mucositis (in 2 patients). Clinical benefit was observed in 18 patients (48.6% of the entire population; 64.3% of those patients with PS>0 at study entry).

CONCLUSION

The combination of gemcitabine and 5-fluorouracil continuous infusion was found to be an active and manageable palliative regimen for heavily pre-treated patients with metastatic CRC.

摘要

背景

对于接受伊立替康和奥沙利铂治疗后病情进展且身体状况良好（PS）的晚期结直肠癌（CRC）患者，尚无标准治疗方案。

患者与方法

我们对37例接受含奥沙利铂 - 伊立替康化疗后病情进展的连续患者，采用吉西他滨1000mg/m²，于第1、8和15天给药，每28天重复，联合5-氟尿嘧啶以200mg/m²/天持续输注的方案进行了研究。

结果

4例（10.8%）患者达到部分缓解（PR），19例（51.4%）患者病情稳定（SD）（PR + SD：62.2%）。中位疾病进展时间和生存期分别为4.2个月和8.9个月。Ⅲ级毒性反应为血小板减少、中性粒细胞减少（3例患者）和黏膜炎（2例患者）。18例患者观察到临床获益（占全部患者的48.6%；在研究入组时PS>0的患者中占64.3%）。